Data as of 3:59pm ET
| +0.04 / +1.62%|
The 5 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 4.00, with a high estimate of 8.00 and a low estimate of 1.37. The median estimate represents a +59.36% increase from the last price of 2.51.
The current consensus among 5 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.